Evidence map›Paper›PMID 41778156›Full record

ArticleFrontiers in endocrinology2026

Case Report: Identification of a

Mengyun Lei, Mei Xue, Huawei Wang, Zhe Dai, Jun Tang

Abstract readCase Reports
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mengyun Lei *Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Mei Xue *Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Huawei WangDepartment of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Zhe DaiDepartment of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Jun TangDepartment of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Maturity-onset diabetes of the young (MODY) is an autosomal dominant monogenic diabetes, with HNF1A-MODY (MODY3) being a common subtype. Standard genetic testing for MODY often focuses on sequencing, which can lead to the misdiagnosis of cases caused by Methods: We evaluated a Chinese family with a clinical diagnosis of maturity-onset diabetes of the young (MODY). Clinical data and peripheral blood samples were collected from family members. A heterozygous Results: A heterozygous Conclusions: This study identifies a

Indexed as

Diabetes Mellitus, Type 2ExonsHepatocyte Nuclear Factor 1-alphaSequence DeletionAdultChinaEast Asian PeopleFemaleHeterozygoteHumansMalePedigreeHepatocyte Nuclear Factor 1-alphaHNF1A protein, humanHNF1AHNF1A-MODYMLPAMODYMODY3

Identifiers

PMID41778156
PMCPMC12950538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.